ES2107609T3 - Polipeptidos sinteticos como inhibidores de vih-1. - Google Patents

Polipeptidos sinteticos como inhibidores de vih-1.

Info

Publication number
ES2107609T3
ES2107609T3 ES93200863T ES93200863T ES2107609T3 ES 2107609 T3 ES2107609 T3 ES 2107609T3 ES 93200863 T ES93200863 T ES 93200863T ES 93200863 T ES93200863 T ES 93200863T ES 2107609 T3 ES2107609 T3 ES 2107609T3
Authority
ES
Spain
Prior art keywords
hiv
inhibitors
polypeptides
administered
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93200863T
Other languages
English (en)
Inventor
Shibo Jiang
Kang Lin
A Robert Neurath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Application granted granted Critical
Publication of ES2107609T3 publication Critical patent/ES2107609T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

POLIPEPTIDAS SINTETICAS BASADAS EN EL VIH ETODOS PARA TRATAR INFECCIONES DE VIH POLIPEPTIDAS DE LA PRESENTE INVENCION TIENEN SECUENCIAS AMINO ACIDAS SUSTANCIALMENTE CORRESPONDIENTES A UNA REGION ESPECIFICADA DEL VIRUS VIH INVENCION PUEDEN SER ADMINISTRADAS EN CANTIDAD EFECTIVA PARA PREVENIR Y TRATAR INFECCIONES DEL VIH USAN PARA INHIBIR LA REPRODUCCION DEL VIRUS VIH LA CITOPATOGENESIS DEBIDA AL VIH NIVELES QUE QUEDAN DENTRO DE MARGENES ACEPTABLES DE CITO ICIDAD.
ES93200863T 1992-03-26 1993-03-25 Polipeptidos sinteticos como inhibidores de vih-1. Expired - Lifetime ES2107609T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/859,923 US5444044A (en) 1992-03-26 1992-03-26 Synthetic polypeptides as inhibitors of HIV-1

Publications (1)

Publication Number Publication Date
ES2107609T3 true ES2107609T3 (es) 1997-12-01

Family

ID=25332065

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93200863T Expired - Lifetime ES2107609T3 (es) 1992-03-26 1993-03-25 Polipeptidos sinteticos como inhibidores de vih-1.

Country Status (9)

Country Link
US (2) US5444044A (es)
EP (1) EP0565164B1 (es)
JP (1) JP3587538B2 (es)
KR (1) KR100269818B1 (es)
AT (1) ATE154363T1 (es)
AU (1) AU667078B2 (es)
CA (1) CA2092519C (es)
DE (1) DE69311427T2 (es)
ES (1) ES2107609T3 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
AU688733B2 (en) 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
US20070202127A1 (en) * 1993-06-07 2007-08-30 Duke University Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
BR9909018A (pt) * 1998-03-23 2001-10-16 Trimeris Inc Processo para a sìntese de um peptìdeo, conjunto de fragmentos de peptìdeo, e, peptìdeo
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US7960504B2 (en) * 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) * 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US6596497B1 (en) 1999-03-17 2003-07-22 New York Blood Center, Inc. Screening of antiviral compounds targeted to the HIV-1 gp41 core structure
CA2395291C (en) 1999-12-16 2012-09-11 Whitehead Institute For Biomedical Research Five-helix protein
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
EP1264177A2 (en) 2000-02-10 2002-12-11 Panacos Pharmaceuticals, Inc. Assay for detection of viral fusion inhibitors
NZ521977A (en) * 2000-03-17 2004-05-28 Panacos Pharmaceuticals Inc A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of HIV envelope proteins
US20030125515A1 (en) * 2001-07-11 2003-07-03 Genfa Zhou End-locked five-helix protein
AU2002351176A1 (en) * 2001-11-29 2003-06-17 Mymetics, Corp. Peptides and use thereof in therapeutic agents against hiv infection
US20040132011A1 (en) * 2002-10-16 2004-07-08 Panacos Pharmaceuticals, Inc. Method for detecting viral inactivating agents
US20080096809A1 (en) * 2003-12-22 2008-04-24 Yeda Research & Development Co. Ltd. Diastereomeric Peptides Useful as Inhibitors of Membrane Protein Assembly
ATE516048T1 (de) * 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
EP2354153A3 (en) * 2004-06-01 2012-05-30 Merck Sharp & Dohme Corp. Stable peptide mimetic of HIV gp41 fusion intermediate
US20090270312A1 (en) * 2005-01-24 2009-10-29 Yechiel Shai Hiv-i gp41 fusion peptides for immunomodulaltion
EP2314320A2 (en) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Method for shielding functional sites or epitopes on proteins
JP4831410B2 (ja) * 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
JP4788958B2 (ja) * 2006-02-28 2011-10-05 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
AU2009260479A1 (en) * 2008-05-28 2009-12-23 New York Blood Center Bifunctional molecules for inhibiting HIV entry
WO2010091373A2 (en) 2009-02-09 2010-08-12 New York Blood Center, Inc. Trimeric hiv fusion inhibitors for treating or preventing hiv infection
CN102883740B (zh) 2010-05-03 2015-10-14 纽约血库公司 用于使hiv失活并阻断hiv的双功能分子
EP2447277A1 (en) 2010-10-28 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Vaccine compositions based on modified gp41 immunogens
US20220409694A1 (en) 2020-02-05 2022-12-29 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Polypeptide, and preparation method therefor and use thereof
CN119613503B (zh) * 2024-07-22 2026-02-06 山西锦波生物医药股份有限公司 可抑制类mers冠状病毒感染的多肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586575B1 (fr) * 1985-08-30 1991-09-06 Lepage Pierre Alain Programmateur d'efforts pour l'entrainement du cycliste
JPH01501547A (ja) * 1986-06-12 1989-06-01 バイオジェン　ナームローズ　ベンノットシャップ Ｈｉｖ感染の病因に関するペプチド
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
AU608413B2 (en) * 1988-03-30 1991-03-28 Abbott Laboratories Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1

Also Published As

Publication number Publication date
KR930019695A (ko) 1993-10-18
CA2092519A1 (en) 1993-09-27
DE69311427D1 (de) 1997-07-17
US5840843A (en) 1998-11-24
AU3537293A (en) 1993-09-30
EP0565164B1 (en) 1997-06-11
US5444044A (en) 1995-08-22
DE69311427T2 (de) 1998-02-12
AU667078B2 (en) 1996-03-07
ATE154363T1 (de) 1997-06-15
JP3587538B2 (ja) 2004-11-10
KR100269818B1 (ko) 2000-10-16
JPH06340698A (ja) 1994-12-13
CA2092519C (en) 2003-03-18
EP0565164A1 (en) 1993-10-13

Similar Documents

Publication Publication Date Title
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
CR20220109A (es) Profármacos antivirales y formulaciones de los mismos
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
UY25869A1 (es) Moduladores de ccr5, formulaciones farmacéuticas, procedimientos y sus usos.
BR9201848A (pt) Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos
EA199901031A1 (ru) Производные бензимидазола
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
PT97754A (pt) Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
ES2125251T3 (es) Inhibidores de la proteasa del vih.
BR0008135A (pt) Composto, métodos para tratar uma infecção por vìrus em um ser humano e para tratar uma infecção pelo vìrus da hepatite b em um ser humano, composição farmacêutica, uso de um composto, método para liberar um composto, pacote para paciente, processo para a preparação de um composto
SA523441639B1 (ar) مركبات بيريدو-تريازين البديلة واستخداماتها
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
AU667078B2 (en) Synthetic polypeptides as inhibitors of HIV-1
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
ATE412666T1 (de) Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
PT88248A (pt) Processo para a preparacao de composicoes farmaceuticas contendo rnas de cadeia dupla com actividade topica
ES2174921T3 (es) Inhibidores de la proteasa del vih.
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
ES2137160T3 (es) Lipopeptidos inductores de los linfocitos t-citotoxicos y utilizacion como vacunas.
ES2166748T3 (es) Represor multivalente de la funcion genica.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)
ES2058100T3 (es) Vacuna combinada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 565164

Country of ref document: ES